Anuj Gaggar
Gilead Sciences (United States)(US)
Publications by Year
Research Areas
Hepatitis C virus research, Hepatitis B Virus Studies, Liver Disease Diagnosis and Treatment, HIV/AIDS drug development and treatment, Virus-based gene therapy research
Most-Cited Works
- → Compassionate Use of Remdesivir for Patients with Severe Covid-19(2020)2,902 cited
- → Remdesivir for 5 or 10 Days in Patients with Severe Covid-19(2020)1,431 cited
- → Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19(2020)1,265 cited
- → CD46 is a cellular receptor for group B adenoviruses(2003)778 cited
- → Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial(2016)538 cited
- → Disruption of the Type III Adenylyl Cyclase Gene Leads to Peripheral and Behavioral Anosmia in Transgenic Mice(2000)470 cited
- → Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial(2016)450 cited
- → Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity(2005)423 cited
- → 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection(2018)416 cited
- → aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis(2020)331 cited